TRPV4 and Hepatic fibrosis: Furthermore, investigations conducted on a CCl4-induced liver fibrosis mouse model demonstrated that the TRPV4 agonist GSK1016790A exacerbated liver fibrosis, whereas the TRPV4 antagonist HC-067047 effectively ameliorated liver collagen fiber deposition and the degree of liver lobular disorder [178].